Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 833-839

  Rubattu, Speranza ^a,b   Sciarretta, Sebastiano ^a   Ciavarella, Giuseppino Massimo ^a   Venturelli, Vanessa ^a   De Paolis, Paola ^c   Tocci, Giuliano ^a   De Biase, Luciano ^a   Ferrucci, Andrea ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Essential hypertension; Left ventricular mass; Metabolic syndrome; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMINO TERMINAL PROATRIUM NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WAIST CIRCUMFERENCE;

EID: 33947099984     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32803cae3c     Document Type: Article

References (37)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation, 2002; 106:3143-3421.
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
3. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
4. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27:2689-2694.
5. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245-1250.
6. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
7. Jones EC, Devereux RB, O'Grady MJ, Schwartz JE, Liu JE, Pickering TG, Roman MJ. Relation of hemodynamic volume load to arterial and cardiac size. J Am Coll Cardiol 1997; 29:1303-1310.
8. Devereux RB, De Simone G, Ganau A, Roman MJ. Pathogenesis of left ventricular hypertrophy. Cardiovasc Risk Factors 1995; 5:109-120.
9. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22:1991-1998.
10. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 2006; 47:881-886.
11. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328.
12. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005; 26:1044-1059.
13. Dickstein K, Larsen AI, Bonarjee V, Thoresen M, Aarsland T, Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol 1995; 76:679-683.
14. Omland T, Bonarjee VV, Nilsen DW, Sundsfjord JA, Lie RT, Thibault G, Dickstein K. Prognostic significance of N-terminal proatrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. Br Heart J 1993; 70:409-414.
15. John SWM, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267:679-681.
16. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RI, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 1997; 94:14730-14735.
17. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocite-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003; 111:1399-1407.
18. Horio T, Nishikimi T, Yoshihara F, Matsuo P, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35:19-24.
19. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, et al. Association of atrial natriuretic peptide and type-A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006; 48:499-505.
20. Sarzani R, Strazzullo P, Salvi F, Iacone R, Pietrucci F, Siani A, et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res 2004; 12:351-356.
21. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, Cola G, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens 1997; 15:1695-1699.
22. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46:660-666.
23. Quinones MA, Douglas PS, Foster E, Gorcsan J 3rd, Lewis JF, Pearlman AS, et al. American Society of Echocardiography; Society of Cardiovascular Anesthesiologists; Society of Pediatric Echocardiography. ACC/AHA clinical competence statement on echocardiography: a report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on clinical competence. J Am Soc Echocardiogr 2003; 16:379-402.
24. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55:613-618.
25. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, Laragh JH. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7:639-650.
26. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20:1251-1260.
27. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976; 37:7.
28. Lind L, Andersson PE, Andren B, Hanni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13:433-438.
29. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600.
30. Khush KK, Gerber IL, McKeown B, Marcus G, Vessey J, Foster E, et al. Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese. Congest Heart Fail 2006; 12:85-90.
31. Morabito D, Vallotton MB, Lang U. Obesity is associated with impaired ventricular protein kinase C-MAP kinase signaling and altered ANP mRNA expression in the heart of adult Zucker rats. J Investig Med 2001; 49:310-318.
32. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline loading. Hypertension 1994; 23 (Suppl I):I-20-I-24.
33. Tsuneyoshi H, Nishina T, Nomoto T, Kanemitsu H, Kawakami R, Unimonh O, et al. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation 2004; 110 (Suppl. II):II-174-II-179.
34. Roberts AM, McCune BK, Sporn MB. TGF-β1: regulation of extracellular matrix. Kidney Int 1992; 41:557-559.
35. Lim JY, Park SJ, Hwang HY, Park EJ, Nam JH, Kim J, Park SI. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol 2005; 39:627-636.
36. Grandi AM, Laurita E, Selva E, Piantanida E, Imperiale D, Giovanella L, et al. Natriuretic peptides as markers of preclinical cardiac disease in obesity. Eur J Clin Invest 2004; 34:342-348.
37. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjornerheim R, Endresen K, Hall C. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142:725-732.